BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35171313)

  • 1. [Transarterial radioembolization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
    Helmberger T; Pereira PL
    Radiologe; 2022 Mar; 62(3):234-238. PubMed ID: 35171313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
    Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
    Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis.
    Mosconi C; Solaini L; Vara G; Brandi N; Cappelli A; Modestino F; Cucchetti A; Golfieri R
    Cardiovasc Intervent Radiol; 2021 May; 44(5):728-738. PubMed ID: 33709272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports.
    Carvalho VO; Galastri FL; Affonso BB; Falsarella PM; Valle LGM; Ferraz-Neto BH; Rezende MB; Motta-Leal-Filho JMD; Garcia RG; Nasser F
    Einstein (Sao Paulo); 2020; 18():eRC4990. PubMed ID: 32130329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [International comparison of radiological aspects of the new German S3 guideline on hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
    Pereira PL; Vogl TJ; Helmberger T
    Radiologe; 2022 Mar; 62(3):253-262. PubMed ID: 35181824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Local and locoregional treatment of intrahepatic cholangiocarcinoma].
    Wacker F; Dewald C
    Radiologe; 2022 Mar; 62(3):247-252. PubMed ID: 34981129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
    Fidelman N; Kerlan RK
    AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].
    Voesch S; Bitzer M; Malek N
    Radiologe; 2022 Mar; 62(3):200-204. PubMed ID: 35147708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma.
    Chan LS; Sze DY; Poultsides GA; Louie JD; Abdelrazek Mohammed MA; Wang DS
    Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1383-1391. PubMed ID: 28432387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Salem R; Lewandowski RJ
    Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.
    Ahmed O; Yu Q; Patel M; Hwang G; Pillai A; Liao CY; Fung J; Baker T
    J Vasc Interv Radiol; 2023 Apr; 34(4):702-709. PubMed ID: 36521794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
    Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
    Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma.
    Seidensticker R; Ricke J; Seidensticker M
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):319-32. PubMed ID: 25966431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization for the treatment of hepatocellular carcinoma.
    Kim HC
    Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.